Back to Results


Title A Long-Term Non-Invasive Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Pediatric Patients with Moderately to Severly Active Crohn’s Disease
Therapeutic Area Crohn's Disease (Tufts Medical Center)
Principal Investigator Jyoti Ramakrishna, MD
Min Age 6 Years
Max Age 17 Years
Gender Both
Contact Su Mon Thwe, MD
More Information


To find out more about children with Crohn’s Disease (CD) to help doctors improve the care of patients with this disease.

Study Details

Inclusion Criteria

  • Patient that has received at least 12 weeks of immunosuppressant therapy prior to registry entry.
  • Parent/guardian hasa voluntarily signed and dated the ICF after the nature of the registry has been explained.

Exclusion Criteria

  • Patients should not be enrolled into the Humira therapy group if they are currently being treated with any investigational agents or are using any investigational procedures.
  • Patients should not be enrolled into the immunosuppressant group if they require ongoing treatment with approved biologics including Humira.

Study Requirements

This is a 10 year study. Patients will be seen every 6 moths during their regularly scheduled visits. There are no blood collections, x rays, CT scans, or MRI’s required.